Products
Fepixnebart Biosimilar Monoclonal Antibody (Epiregulin) for Research
Cat No.: GMP-Bios-INN-1202
Anti-EREG therapeutic antibody (Pre-made Fepixnebart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Fepixnebart (development code LY-3016859) is a humanized monoclonal antibody targeting TGF-alpha (TGFA) and epiregulin (EREG). It is developed by Eli Lilly and Company for pain conditions and diabetic nephropathies. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1202-1mg | 1mg | 3090 |
| GMP-Bios-INN-1202-10mg | 10mg | |
| GMP-Bios-INN-1202-100mg | 100mg | |
| GMP-Bios-INN-1202-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Fepixnebart biosimilar, Whole mAb, Anti-EREG Antibody: Anti-EREG/Epiregulin/Proepiregulin/ER therapeutic antibody |
| INN Name | Fepixnebart |
| Target | EREG |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 5kn5:AB |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Eli Lilly and Company |
| Conditions Approved | na |
| Conditions Active | Back pain;Neuropathic pain;Pain;Diabetic nephropathies |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
